A Blessing for Breast Cancer patients: Supreme Court Strikes Down Patents on “Natural” Genes
On June 13 the Supreme Court denied the intellectual property rights claims by Myriad Genetics on the BRCA1 and BRCA2 genes used to evaluate a woman’s risk of breast and ovarian cancers. Hooray! It’s always seemed wrong that anyone could own any part of the human genome. Myriad Genetics built a $450-million-a-year business on these two gene markers. Women with…
bmichaelsJune 29, 2013










